TEMPUS

Tempus introduced its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII... Nature Biotechnology Study Reveals that Tempus' xT Platform Increases Cancer Patients' Personalized Therapeutic Opportunities Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing. A Pan-cancer Organoid Platform for Precision Medicine Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity..

Also known as: Tempus Labs, Inc.

Primary location: Chicago United States